Led by Caroline Huber, Associate Director of Policy and Economics, a surprising new study was recently published in The Journal of Infectious Diseases, estimating the overlooked social, economic and health impacts of the 2013-2016 West Africa Ebola crisis.
In a special commentary appearing in STAT News, Jacki Chou, Senior Director, Policy & Economics, and her co-author discuss overcoming 5 critical challenges in the US biosimilars marketplace, offering some strategic policy recommendations for the consideration of key healthcare stakeholders. […]
In the latest edition of the Journal of Clinical Pathways (JCP), Zachary Bessette summarizes PHE Senior Research Economist Jim Baumgardner’s recent ASH presentation, focused on studying the cost-effectiveness of novel CAR-T treatments. In the study, Dr. Baumgardner’s team asserts that the introduction of CAR-T therapies represents a major break from the trend of declining incremental effectiveness and provides similar cost-effectiveness to other innovations.
Speaking with AIS Health’s Angela Maas, Senior Research Economist Jason Shafrin addresses the Trump Administration’s proposal to establish flat rate prescription reimbursement to physicians—calling out several of the pros and cons.
In the most recent Radar on Specialty Pharmacy, Senior Research Economist Jason Shafrin addresses the Trump Administration’s proposed changes to the International Pricing Index, and how these changes might impact future drug development and innovation.
For more information, or to learn how to change your cookies preferences, please click here.